This newsletter presents you the following key sessions:
1. Blood test for early detection of breast cancer in high-risk patients
2. Adjuvant radiotherapy does not impact overall survival and loco-regional recurrence beyond ten years of
follow-up in patients with early breast cancer
3. Matching adjusted indirect comparison shows superior survival with ribociclib vs. palbociclib in
first-line HR+/HER2- advanced breast cancer
4. Negative prognostic impact of higher residual disease-TILs after anti-HER2+ neoadjuvant therapy
SMPC